Table 2 ICU characteristics of patients with and without severe liver dysfunction
Variables | All (n = 72) | No liver dysfunction (n = 50) | Severe liver dysfunction (n = 22) | p-value |
|---|---|---|---|---|
Disease severity | ||||
SAPS II—admission (pts.) | 41 (35–48.8) | 40 (32–45) | 48 (39–52) | 0.006 |
SOFA—admission (pts.) | 6 (3–11) | 6 (3–11) | 7 (3–9) | 0.938 |
SOFA—24 h (pts.) | 8 (4–13) | 7 (3–11) | 10 (7–15) | 0.075 |
Respiratory support | ||||
Invasive MV | 53 (74) | 32 (64) | 21 (95) | 0.004 |
Duration of MV (days) | 12.5 (7.3–25.8) | 13 (6–27) | 12 (8–25) | 0.965 |
Non-invasive ventilation | 7 (10) | 3 (6) | 4 (18) | 0.182 |
High-flow nasal cannula | 25 (35) | 16 (32) | 9 (41) | 0.454 |
ECMO | 12 (17) | 6 (12) | 6 (27) | 0.106 |
Worst paO2/FiO2 | 110 (71–151) | 117 (83–155) | 82 (58–114) | 0.033 |
ARDS | ||||
No ARDS | 22 (31) | 20 (40) | 2 (9) | 0.007 |
Mild | 3 (4) | 2 (4) | 1 (5) | 0.651 |
Moderate | 19 (26) | 13 (26) | 6 (27) | 0.258 |
Severe | 28 (39) | 15 (30) | 13 (59) | 0.225 |
ARDS—management | ||||
Prone positioning | 41 (57) | 25 (50) | 16 (73) | 0.036 |
Neuromuscular blockade | 18 (25) | 10 (20) | 8 (36) | 0.001 |
Inhaled vasodilator | 20 (28) | 8 (16) | 12 (55) | 0.111 |
Glucocorticoid therapy | 26 (36) | 12 (24) | 14 (64) | 0.001 |
Procedures/therapies | ||||
Vasopressors | 57 (79) | 36 (72) | 21 (95) | 0.027 |
Renal replacement therapy | 34 (47) | 15 (30) | 19 (86) | < 0.001 |
Therapeutic anticoagulation | 33 (46) | 19 (38) | 14 (64) | 0.166 |
Antibiotic therapy | 69 (96) | 48 (96) | 21 (95) | 0.493 |
Experimental therapy | ||||
Lopinavir, ritonavir | 8 (11) | 5 (10) | 3 (14) | 0.187 |
Remdesivir | 2 (3) | 1 (2) | 1 (5) | 0.521 |
Tocilizumab | 3 (4) | 0 (0) | 3 (14) | 0.026 |
Plasma exchange | 2 (3) | 1 (2) | 1 (5) | 0.521 |
Immunoglobulins | 2 (3) | 2 (4) | 0 (0) | 0.479 |
Laboratory results | ||||
AST—peak (U/l) | 140 (63–326) | 88 (50–147) | 746 (279–4293) | < 0.001 |
ALT—peak (U/l) | 79 (39–172) | 59 (32–103) | 348 (127–720) | < 0.001 |
Bilirubin—peak (mg/dl) | 0.8 (0.6–1.8) | 0.5 (0.4–0.7) | 2.6 (1.7–4.5) | < 0.001 |
pH—nadir | 7.27 (7.14–7.39) | 7.3 (7.19–7.39) | 7.19 (7.07–7.29) | 0.015 |
Lactate—peak | 2.5 (1.7–5) | 1.9 (1.7–2.9) | 6.4 (3.4–12.8) | < 0.001 |
INR—admission | 1.1 (1–1.2) | 1.1 (1–1.1) | 1.1 (1.03–1.2) | 0.082 |
Thrombocytes—admission | 204 (116–284) | 227 (140–300) | 161 (60–238) | 0.078 |
Ferritin—admission | 1493 (911–3009) | 1249 (768–2326) | 2395 (1126–6253) | 0.030 |
IL-6—admission | 134 (56–412) | 104 (54–243) | 279 (92–975) | 0.016 |
LDH—admission | 446 (364–603) | 424 (364–577) | 566 (380–681) | 0.245 |
Complications—ICU stay | ||||
Pulmonary embolism | 3 (4) | 1 (2) | 2 (9) | 0.219 |
Deep vein thrombosis | 11 (15) | 7 (14) | 4 (18) | 0.448 |
Cardiac arrest | 11 (15) | 5 (10) | 6 (27) | 0.068 |
Septic shock | 32 (44) | 16 (32) | 16 (73) | 0.001 |